Clinical Trials Logo

Arterial Hypertension clinical trials

View clinical trials related to Arterial Hypertension.

Filter by:

NCT ID: NCT04065620 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Ambulatory Blood Pressure in HFPEF Outcomes Global Registry

HFPEFGlobal
Start date: March 1, 2020
Phase:
Study type: Observational

Heart failure and preserved ejection fraction (HFPEF) is a disease with increasing prevalence world wide. Due to its etiological and prognostic relationship with hypertension, it is highly interesting to know the characteristics and influence of Blood pressure levels and of the hemodynamic biomarkers, measured by Ambulatory Blood Pressure measurement in the outcome of patients with (HF-PEF), defined by the risk of cardiovascular morbidity and mortality (hospital re-admissions, emergency room visits, functional decline and mortality). The investigators consider other factors such as Frailty, comorbidities, and the baseline functional capacity to asses the prognostic value.

NCT ID: NCT04055285 Not yet recruiting - Atrial Fibrillation Clinical Trials

Effect of Renal Denervation on Atrial Fibrillation

ERDAF
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The purpose of the ERDAF study (Effect of Renal Denervation on Atrial Fibrillation) is to evaluate the renal sympathetic denervation in patients with resistant arterial hypertension and symptomatic paroxysmal or persistent atrial fibrillation(AF) in order to show if there is a reduction in the AF-related symptoms, the AF recurrence rate, and the total burden (symptomatic and/or asymptomatic) of the arrhythmia. To the best of our knowledge, ERDAF is the first randomized study, which is going to evaluate the effect of RDN [without pulmonary vein isolation (PVI)] on AF recurrence profile and AF ''burden'' using continuous long-term rhythm monitoring via ILRs for a period of 18 months. Hypothesis Renal sympathetic denervation in patients with resistant hypertension and symptomatic paroxysmal or persistent atrial fibrillation reduces AF recurrences, total AF "burden" (asymptomatic / symptomatic) and limits the AF-related symptoms.

NCT ID: NCT04023565 Recruiting - Metabolic Syndrome Clinical Trials

Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

COMPOSER
Start date: March 11, 2019
Phase: Phase 4
Study type: Interventional

The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on the previously administered two-component combination antihypertensive therapy. Open-label non-comparative prospective study for 24 week for each patient.

NCT ID: NCT03982758 Recruiting - Clinical trials for Arterial Hypertension

Acute Effect of Isometric Exercise on Blood Pressure in Hypertensive Patients

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

International recommendations advocate dynamic or isometric strength training as an adjunct to aerobic exercise. Due to a lack of consensus, this research addresses the acute effects of isometric exercises by handgrip or lower limb isometry as a hypotensive strategy in hypertensive adults.

NCT ID: NCT03963934 Not yet recruiting - Clinical trials for Arterial Hypertension

Feasibility of a Program on a Nurse-led Telephone 6-month-follow-up for Uncontrolled Hypertensive Women

PreDynamiques
Start date: December 1, 2019
Phase: N/A
Study type: Interventional

This study evaluate the feasibility of a 6-month personalized support program for hypertensive and non-observant women, led by nurses by telephone follow-up.

NCT ID: NCT03917758 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

GliRACo1
Start date: October 10, 2018
Phase: N/A
Study type: Interventional

Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.

NCT ID: NCT03814148 Withdrawn - Clinical trials for Arterial Hypertension

Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

Start date: June 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Leningrado 5 association on the treatment of hypertension.

NCT ID: NCT03814109 Withdrawn - Clinical trials for Arterial Hypertension

Efficacy and Safety of Leningrado Association in the Treatment of Hypertension

Start date: April 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Leningrado association on the treatment of hypertension.

NCT ID: NCT03730116 Completed - Clinical trials for Arterial Hypertension

Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril

STYLE
Start date: November 14, 2018
Phase:
Study type: Observational

Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice. Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

NCT ID: NCT03722524 Completed - Clinical trials for Arterial Hypertension

The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension

TRICOLOR
Start date: October 1, 2018
Phase:
Study type: Observational

The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy. The main aim of this study to assess the antihypertensive effectiveness effect on the 24-hour BP profile, as well as tolerability of and compliance to the treatment with a triple FDC of amlodipine / indapamide / perindopril arginine in hypertensive patients in the real clinical practice. Type of program: Multicenter, observational, non-controlled, open-label program. Investigators: Cardiologists and outpatient (primary care) physicians (general practitioners). Number of patients: 1,300 hypertensive patients.